TY - JOUR
T1 - Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties
AU - Sato, Masakazu
AU - Kawana, Kei
AU - Adachi, Katsuyuki
AU - Fujimoto, Asaha
AU - Taguchi, Ayumi
AU - Fujikawa, Tomona
AU - Yoshida, Mitsuyo
AU - Nakamura, Hiroe
AU - Nishida, Haruka
AU - Inoue, Tomoko
AU - Ogishima, Juri
AU - Eguchi, Satoko
AU - Yamashita, Aki
AU - Tomio, Kensuke
AU - Arimoto, Takahide
AU - Wada-Hiraike, Osamu
AU - Oda, Katsutoshi
AU - Nagamatsu, Takeshi
AU - Osuga, Yutaka
AU - Fujii, Tomoyuki
PY - 2017/3
Y1 - 2017/3
N2 - The characteristics of ovarian cancers that showed low activation of glycolysis were investigated. Using medical records of patients with ovarian cancers who had undergone fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) prior to their primary surgery at the University of Tokyo Hospital between 2010 and 2015, we identified cases with a low uptake of FDG in PET/CT. We considered the maximum standardized uptake value (SUVmax) as the degree of glucose uptake. We investigated the properties which may account for the low activation of glycolysis in vitro. The expression level of alanine, serine, cysteine-preferring transporter 2 (ASCT2, a glutamine influx transporter), system L-type amino acid transporter 1 (LAT1, a glutamine efflux transporter) and glucose transporter 1 (GLUT1, a glucose influx transporter) were investigated by western blotting. The phosphorylation level of AMP-activated protein kinase (AMPK), which is one of the metabolic sensors, was also investigated. Most of the cases with a low uptake SUVmax were limited to patients with ovarian clear cell carcinoma (CCC). We obtained cancer stem cell (CSC)-like properties from CCC cell lines, and compared the expression levels of transporters between non-CSCs and CSCs. Whereas the expression level of ASCT2 was nearly unchanged between non-CSCs and CSCs, the expression levels of LAT1 and GLUT1 were decreased in CSCs compared to non-CSCs. The phosphorylation level of AMPK was reduced in CSCs compared to non-CSCs. In conclusion, we suggested that ovarian CCC showed low activation of glycolysis, and this may reflect glutaminolysis of its CSC-like properties.
AB - The characteristics of ovarian cancers that showed low activation of glycolysis were investigated. Using medical records of patients with ovarian cancers who had undergone fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) prior to their primary surgery at the University of Tokyo Hospital between 2010 and 2015, we identified cases with a low uptake of FDG in PET/CT. We considered the maximum standardized uptake value (SUVmax) as the degree of glucose uptake. We investigated the properties which may account for the low activation of glycolysis in vitro. The expression level of alanine, serine, cysteine-preferring transporter 2 (ASCT2, a glutamine influx transporter), system L-type amino acid transporter 1 (LAT1, a glutamine efflux transporter) and glucose transporter 1 (GLUT1, a glucose influx transporter) were investigated by western blotting. The phosphorylation level of AMP-activated protein kinase (AMPK), which is one of the metabolic sensors, was also investigated. Most of the cases with a low uptake SUVmax were limited to patients with ovarian clear cell carcinoma (CCC). We obtained cancer stem cell (CSC)-like properties from CCC cell lines, and compared the expression levels of transporters between non-CSCs and CSCs. Whereas the expression level of ASCT2 was nearly unchanged between non-CSCs and CSCs, the expression levels of LAT1 and GLUT1 were decreased in CSCs compared to non-CSCs. The phosphorylation level of AMPK was reduced in CSCs compared to non-CSCs. In conclusion, we suggested that ovarian CCC showed low activation of glycolysis, and this may reflect glutaminolysis of its CSC-like properties.
KW - Cancer stem cells
KW - Clear cell carcinoma
KW - Fluorodeoxyglucose positron emission tomography/computed tomography
KW - Glutaminolysis
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=85013339742&partnerID=8YFLogxK
U2 - 10.3892/or.2017.5398
DO - 10.3892/or.2017.5398
M3 - 記事
C2 - 28112360
AN - SCOPUS:85013339742
SN - 1021-335X
VL - 37
SP - 1883
EP - 1888
JO - Oncology Reports
JF - Oncology Reports
IS - 3
ER -